Related Experiment Video
Updated: May 18, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Rivaroxaban in atrial fibrillation
Mariano A Giorgi1, Lucas San Miguel
1Cardiology Service, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno, Buenos Aires, Argentina. marianoagiorgi@hotmail.com
Vascular Health and Risk Management
|September 14, 2012
Summary
Rivaroxaban offers a viable alternative to warfarin for preventing stroke in atrial fibrillation, demonstrating comparable efficacy with potential real-world advantages. Novel oral anticoagulants are now a practical option for managing thromboembolic risk.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Warfarin, a traditional oral anticoagulant, manages thromboembolic risk in atrial fibrillation but has variable efficacy due to challenges in maintaining the International Normalized Ratio (INR) within the therapeutic range (2.00-3.00).
- Limited time spent within the therapeutic INR range (61%-68%) with warfarin contributes to hemorrhagic risks and suboptimal anticoagulation.
- Novel oral anticoagulants (NOACs) have been developed to improve the safety and efficacy profile of oral anticoagulation therapy.
Purpose of the Study:
- To evaluate rivaroxaban, a novel oral anticoagulant, as an alternative to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation.
- To compare the efficacy and safety of rivaroxaban with warfarin in the ROCKET-AF trial.
- To discuss the pharmacokinetic and pharmacoeconomic properties of rivaroxaban in comparison to other NOACs like dabigatran and apixaban.
Main Methods:
- The ROCKET-AF trial assessed the efficacy of rivaroxaban compared to warfarin in patients with nonvalvular atrial fibrillation.
- Key endpoints included stroke and systemic embolism prevention.
- INR monitoring and time in therapeutic range (TTR) were evaluated for both warfarin and rivaroxaban groups.
Main Results:
- Rivaroxaban demonstrated a 12% reduction in the primary endpoint incidence compared to warfarin (HR 0.88; P < 0.001 for noninferiority).
- Patients in the ROCKET-AF trial spent 55% of the time within the therapeutic INR range, lower than observed in RE-LY (64%) and ARISTOTLE (66%) trials.
- Despite lower TTR, rivaroxaban's performance suggests potential real-world applicability and favorable pharmacokinetic/pharmacoeconomic profiles.
Conclusions:
- Novel oral anticoagulants, including rivaroxaban, represent a viable and commercially available alternative to vitamin K antagonists for preventing thromboembolic complications in atrial fibrillation.
- Rivaroxaban is an attractive option, offering comparable efficacy to warfarin with potential advantages in ease of use and pharmacoeconomic properties.
- Further widespread use will provide a clearer understanding of rivaroxaban's long-term impact in managing atrial fibrillation-related thromboembolic risk.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...